Idiopathic adult intussusception

Intussusception is an uncommon cause of abdominal pain in adults and poses diagnostic challenges for emergency physicians, due to its varied presenting symptoms and time course. Diagnosis is thus often delayed and results in surgical intervention due to the development of bowel ischaemia. We report on a young patient who presented with an ileo-ileal intussusception in whom there were no underlying lesions identified as a causal factor

What if Supersymmetry Breaking Unifies beyond the GUT Scale?

We study models in which soft supersymmetry-breaking parameters of the MSSM become universal at some unification scale, $M_{in}$, above the GUT scale, \mgut. We assume that the scalar masses and gaugino masses have common values, $m_0$ and $m_{1/2}$ respectively, at $M_{in}$. We use the renormalization-group equations of the minimal supersymmetric SU(5) GUT to evaluate their evolutions down to \mgut, studying their dependences on the unknown parameters of the SU(5) superpotential. After displaying some generic examples of the evolutions of the soft supersymmetry-breaking parameters, we discuss the effects on physical sparticle masses in some specific examples. We note, for example, that near-degeneracy between the lightest neutralino and the lighter stau is progressively disfavoured as $M_{in}$ increases. This has the consequence, as we show in $(m_{1/2}, m_0)$ planes for several different values of $\tan \beta$, that the stau coannihilation region shrinks as $M_{in}$ increases, and we delineate the regions of the $(M_{in}, \tan \beta)$ plane where it is absent altogether. Moreover, as $M_{in}$ increases, the focus-point region recedes to larger values of $m_0$ for any fixed $\tan \beta$ and $m_{1/2}$. We conclude that the regions of the $(m_{1/2}, m_0)$ plane that are commonly favoured in phenomenological analyses tend to disappear at large $M_{in}$.Comment: 24 pages with 11 eps figures; references added, some figures corrected, discussion extended and figure added; version to appear in EPJ

Relating the CMSSM and SUGRA models with GUT scale and Super-GUT scale Supersymmetry Breaking

While the constrained minimal supersymmetric standard model (CMSSM) with universal gaugino masses, m_{1/2}, scalar masses, m_0, and A-terms, A_0, defined at some high energy scale (usually taken to be the GUT scale) is motivated by general features of supergravity models, it does not carry all of the constraints imposed by minimal supergravity (mSUGRA). In particular, the CMSSM does not impose a relation between the trilinear and bilinear soft supersymmetry breaking terms, B_0 = A_0 - m_0, nor does it impose the relation between the soft scalar masses and the gravitino mass, m_0 = m_{3/2}. As a consequence, tan(\beta) is computed given values of the other CMSSM input parameters. By considering a Giudice-Masiero (GM) extension to mSUGRA, one can introduce new parameters to the K\"ahler potential which are associated with the Higgs sector and recover many of the standard CMSSM predictions. However, depending on the value of A_0, one may have a gravitino or a neutralino dark matter candidate. We also consider the consequences of imposing the universality conditions above the GUT scale. This GM extension provides a natural UV completion for the CMSSM.Comment: 16 pages, 11 figures; added erratum correcting several equations and results in Sec.2, Sec.3 and 4 remain unaffected and conclusions unchange

Examining leptogenesis with lepton flavor violation and the dark matter abundance

Within a supersymmetric (SUSY) type-I seesaw framework with flavor-blind universal boundary conditions, we study the consequences of requiring that the observed baryon asymmetry of the Universe be explained by either thermal or non-thermal leptogenesis. In the former case, we find that the parameter space is very constrained. In the bulk and stop-coannihilation regions of mSUGRA parameter space (that are consistent with the measured dark matter abundance), lepton flavor-violating (LFV) processes are accessible at MEG and future experiments. However, the very high reheat temperature of the Universe needed after inflation (of about 10^{12} GeV) leads to a severe gravitino problem, which disfavors either thermal leptogenesis or neutralino dark matter. Non-thermal leptogenesis in the preheating phase from SUSY flat directions relaxes the gravitino problem by lowering the required reheat temperature. The baryon asymmetry can then be explained while preserving neutralino dark matter, and for the bulk or stop-coannihilation regions LFV processes should be observed in current or future experiments.Comment: 20 pages, 5 figures, 1 tabl

Policy design for the Anthropocene

This is the author accepted manuscript. The final version is available from Nature Research via the DOI in this recordToday, more than ever, ‘Spaceship Earth’ is an apt metaphor as we chart the boundaries for a safe planet1. Social scientists both analyse why society courts disaster by approaching or even overstepping these boundaries and try to design suitable policies to avoid these perils. Because the threats of transgressing planetary boundaries are global, long-run, uncertain and interconnected, they must be analysed together to avoid conflicts and take advantage of synergies. To obtain policies that are effective at both international and local levels requires careful analysis of the underlying mechanisms across scientific disciplines and approaches, and must take politics into account. In this Perspective, we examine the complexities of designing policies that can keep Earth within the biophysical limits favourable to human life.Stockholm Resilience CentreBECC - Biodiversity and Ecosystem services in a Changing ClimateMistra Carbon Exi

Varespladib and cardiovascular events in patients with an acute coronary syndrome: the VISTA-16 randomized clinical trial

IMPORTANCE: Secretory phospholipase A2(sPLA2) generates bioactive phospholipid products implicated in atherosclerosis. The sPLA2inhibitor varespladib has favorable effects on lipid and inflammatory markers; however, its effect on cardiovascular outcomes is unknown. OBJECTIVE: To determine the effects of sPLA2inhibition with varespladib on cardiovascular outcomes. DESIGN, SETTING, AND PARTICIPANTS: A double-blind, randomized, multicenter trial at 362 academic and community hospitals in Europe, Australia, New Zealand, India, and North America of 5145 patients randomized within 96 hours of presentation of an acute coronary syndrome (ACS) to either varespladib (n = 2572) or placebo (n = 2573) with enrollment between June 1, 2010, and March 7, 2012 (study termination on March 9, 2012). INTERVENTIONS: Participants were randomized to receive varespladib (500 mg) or placebo daily for 16 weeks, in addition to atorvastatin and other established therapies. MAIN OUTCOMES AND MEASURES: The primary efficacy measurewas a composite of cardiovascular mortality, nonfatal myocardial infarction (MI), nonfatal stroke, or unstable angina with evidence of ischemia requiring hospitalization at 16 weeks. Six-month survival status was also evaluated. RESULTS: At a prespecified interim analysis, including 212 primary end point events, the independent data and safety monitoring board recommended termination of the trial for futility and possible harm. The primary end point occurred in 136 patients (6.1%) treated with varespladib compared with 109 patients (5.1%) treated with placebo (hazard ratio [HR], 1.25; 95%CI, 0.97-1.61; log-rank P = .08). Varespladib was associated with a greater risk of MI (78 [3.4%] vs 47 [2.2%]; HR, 1.66; 95%CI, 1.16-2.39; log-rank P = .005). The composite secondary end point of cardiovascular mortality, MI, and stroke was observed in 107 patients (4.6%) in the varespladib group and 79 patients (3.8%) in the placebo group (HR, 1.36; 95% CI, 1.02-1.82; P = .04). CONCLUSIONS AND RELEVANCE: In patients with recent ACS, varespladib did not reduce the risk of recurrent cardiovascular events and significantly increased the risk of MI. The sPLA2inhibition with varespladib may be harmful and is not a useful strategy to reduce adverse cardiovascular outcomes after ACS. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT01130246. Copyright 2014 American Medical Association. All rights reserved

Indexing Information for Data Forensics

We introduce novel techniques for organizing the indexing structures of how data is stored so that alterations from an original version can be detected and the changed values specifically identified. We give forensic constructions for several fundamental data structures, including arrays, linked lists, binary search trees, skip lists, and hash tables. Some of our constructions are based on a new reduced-randomness construction for nonadaptive combinatorial group testing

In vitro analysis of the cytotoxicity and the antimicrobial effect of four endodontic sealers

<p>Abstract</p> <p>Introduction</p> <p>The aim of this study was to investigate <it>in vitro </it>the cytotoxicity and antibacterial properties of four different endodontic sealers using human periodontal ligament fibroblast cell proliferation and visual analysis of growth inhibition.</p> <p>Methods</p> <p>A silicone (GuttaFlow), silicate (EndoSequence BC), zinc oxide eugenol (Pulp Canal Sealer EWT) and epoxy resin (AH Plus Jet) based sealer were incubated with PDL fibroblasts (10⁴cells/ml, n = 6) up to 96 h. Cell proliferation (RFU) was determined by means of the Alamar Blue assay. Cell growth and morphology was visualized by means of fluorescent dyes. Possible antibacterial properties of the different sealers were visualized by means of SEM (<it>Enterococcus faecalis; Parvimonas micra</it>).</p> <p>Results</p> <p>Fibroblast proliferation depended on sealer and cultivation time. After 72 and 96 h GuttaFlow and EndoSequence BC showed relatively non-cytotoxic reactions, while Pulp Canal Sealer EWT and AH Plus Jet caused a significant decrease of cell proliferation (p < 0.001). Visualization of cell growth and morphology with various fluorescent dyes supplemented the results. No antibacterial effect of EndoSequence BC to <it>P. micra </it>was found, whereas GuttaFlow showed a weak, Pulp Canal Sealer EWT and AH Plus Jet extensive growth inhibition. Also, no antibacterial effect of GuttaFlow, EndoSequence BC or AH Plus Jet to <it>E. faecalis </it>could be detected.</p> <p>Conclusions</p> <p>These <it>in vitro </it>findings reveal that GuttaFlow and EndoSequence BC can be considered as biocompatible sealing materials. However, prior to their clinical employment, studies regarding their sealing properties also need to be considered.</p